takeaway meet manag
messag guggenheim therapeut research team host bu tour
investor san francisco bay area april met manag
team small mid-siz compani includ nc
buy buy note summar takeaway
takeaway manag meet pleas see page detail
nc foundat year compani pursu fast-follow approach
toward allogen car-t therapi manag highlight goal overcom
key drawback autolog car-t therapi build pfe prior invest
categori allo strategi includ invest heavili manufactur capabl
sustain fast follow strategi near-term pursu bcma-
target product eventu expans solid tumor longer term like
foundat year compani expect addit ind clear
bcma program clinic program initi lymphoma
multipl myeloma clinic data like begin emerg
accord manag
neutral still qs head earli june valrox
updat head valrox hemophilia updat june/juli focus qs
factor trajectori potenti acceler file bmrn manufactur capabl
strategi gene therapi broadli think valrox approv expect
compani announc acceler file strategi manufactur front
compani readi current compani scale continu see strateg
valu intern extern compani wholli own viral vector manufactur
said cautiou share head valrox updat given unknown around
durabl still dont know there declin see re-emerg
competit space once/roch potenti acknowledg
robust base busi emerg non-gen therapi pipelin think larg
reflect current level maintain neutral rate
bold buy asgct updat key xlmtm regulatori path come
focu upcom xlmtm data updat asgct may et includ
biopsi data higher dose cohort key data point help
compani decid dose move forward decis dose may
readi meet given data hot press management track
final bla plan newli announc program dmd bold note
plan aggress develop far behind may seem
compani intern manufactur capabl continu see uniqu
valuabl asset key factor abil acceler develop bottom line
continu like bold share head near term asgct updat expect
regulatori pipelin progress reiter buy
derm buy qbrexza updat reassur lebri phase plan track
detail phase data eadv focu meet next step lebri post
phase result recent revers qbrexza volum growth follow termin
co-pay card believ derm qbrexza commerci plan improv drug
long-term commerci return post transit remain particularli enthusiast
lebri clinic profil atop dermat opportun indic well
potenti strateg valu lebri could offer larger biopharma compani
buy confid cabometyx sale growth potenti despit
competit sever life-cycle manag opportun underway consist
page analyst certif import disclosur
previou commentari manag remain confid opportun
data fda approv tyrosin kinas inhibitor tki combin
front line rcc mirror recent commentari receiv rcc kol management
highlight commerci liver cancer highli
synergist rcc given larg degre prescrib overlap provid second
growth driver howev caveat market system therapi
take time develop sever potenti label extend trial activ cabometyx
remain track line combin phase trial rcc
underway could potenti lead cabo acceler
approv differenti thyroid cancer dtc next wave pivot trial seek
addit label expans start later year busi develop
perspect narrow focu toward under-appreci distress asset later-
clinic stage develop mindset similar valu investor
ftsv buy well-posit key trial updat mid-year
given signific inbound investor interest last week focus question
manag expect head phase ii result non-
hodgkin lymphoma nhl eha icml could potenti
valid phase signal observ combin retuximab ftsv guid
present result addit dlbcl fl patient treat
kg dose note per fda recommend new patient
studi harder-to-treat car-t therapy-inelig patient unlik initi
phase portion point ftsv plan random pivot trial relapsed/
refractori dlbcl base-cas assumpt pend plan fda-discuss
also acknowledg morphosi mor recent success obtain fda-buy-in
acceler file strategi novel-novel combin first vidaza combin
data aml/md present poster could potenti valid
synergi observ prolif combin two agent trial solid tumor
indic ovarian cancer colorect cancer remain track addit updat
guid first data partner roch rhhbi read
buy full data come june voxelotor commerci prep
underway investor question primarili focus remain element
data packag necessari complet full nda voxelotor oral hemoglobin
modifi sickl cell diseas compani current commerci
prepar voxelotor takeaway discuss includ full data
come eha june expect surpris dataset data form
basi complet nda submiss voxelotor roll nda underway
complet submiss track commerci prepar voxelotor
launch on-going msl alreadi educ physician payor sale rep
hire progress view develop posit consid voxelotor
like approv fda reiter buy pt
buy daxi bla end set compel risk-reward
aesthet launch multipl therapeut catalyst despit recent
pullback biopharma broadli remain confid daxi differenti
long-dur profil importantli dr gallagh believ daxi longer-act profil
replic ph cervic dystonia studi result key valu driver
view also encourag mr sjut emphasi daxi abil captur
innov premium aesthet therapeut reiter buy rate pt
buy track multipl bispecif antibodi pipelin updat
highlight modular natur antibodi platform key
differenti factor competitor key driver behind broad set
partnership novn among other manag remain
confid abil potenti overcom partial hold
main constraint time requir pull togeth data program fda
request bispecif antibodi pipelin remain track three late clinic
data updat includ first phase data
 well neuroendocrin tumor net
 partnership novn soon yield anoth drug candid clinic
page analyst certif import disclosur
nc foundat year compani pursu fast-follow
takeaway aim overcom key drawback autolog car-t therapi build
pfe prior invest allo strategi includ invest manufactur capabl
sustain fast follow near-term plan eventu expans solid tumor longer term
like foundat year expect addit ind clear clinic program
initi clinic data like
aim overcom key drawback autolog car-t therapi build pfe prior
invest although year old follow spin-out management
highlight built sever year worth previou workflow develop
capit invest well kite c-suit experi success dr david chang allo ceo
dr ari belldegrun allo execut chairman deep root cellular therapi develop
work kite part pioneer effort autolog car-t
asset yescarta although autolog therapi date shown impress efficaci hematolog
malign remain numer drawback notabl singl dose yield per patient lengthi
manufactur time day high rate manufactur failur high product cost
impair start materi cell sick cancer patient along sever
compani develop next gener car-t product candid shift toward allogen
healthy-donor deriv off-the-shelf approach cellular therapi allo initi product candid allo-
incorpor two gene edit step remov tcr order avoid graft vs host
diseas delet allow use antibodi part
precondit regimen help creat increas window donor t-cell persist
patient immun system ultim reject cell phase data present
valid concept accord manag sinc patient receiv standard
cy/flu lymphodeplet regimen achiev cr/cri patient receiv
mab lymphodeplet regimen cr/cri
allo strategi includ invest manufactur capabl sustain fast follow
near-term strategi eventu expans solid tumor longer term manag
reiter plan differenti heavili commit invest in-hous
manufactur capabl commit evidenc allo recent announc
enter leas build squar foot cell therapi manufactur facil newark california
addit team confirm half personnel hire growth phase
peopl past year manufactur depart manag state
believ effici in-hous manufactur posit well near-term compon
develop strategi includ fast follow pursu clinic valid target
near-term strategi driven develop allo first asset target
lymphoma target bcma myeloma target
aml longer term plan expand focu solid tumor leverag next gener
technolog alreadi disclos plan advanc asset target renal cell
carcinoma small cell lung cancer
like foundat year expect one addit ind clear
clinic program initi clinic data like come current
evalu on-going servier-run phase trial patient given
page analyst certif import disclosur
manufactur challeng enrol recent stall updat result studi like
wont avail next year accord manag ind clear
januari phase studi alpha track initi patient r/r larg b-cell
lymphoma follicular lymphoma first clinic data meaning number treat patient
trial like avail next year accord manag recal ident design
base allo optim gmp-grade manufactur process addit
guid toward ind submiss clear initi phase trial anti-bcma asset
r/r multipl myeloma year
page analyst certif import disclosur
neutral still qs head earli june
compani particip dr hank fuch presid world-wide dr robert baffi evp
technic oper spiegelman evp cfo
takeaway head valrox hemophilia updat june/juli focus qs
factor trajectori potenti acceler file bmrn manufactur capabl strategi gene
therapi broadli think valrox approv expect compani announc
acceler file strategi manufactur front compani readi current
compani scale continu see strateg valu intern extern compani
wholli own viral vector manufactur said cautiou share head valrox
updat given unknown around durabl still dont know there declin see
re-emerg competit space once/roch potenti acknowledg
robust base busi emerg non-gen therapi pipelin think larg reflect
current level maintain neutral rate
earli june well get whole story- abr data fviii activ level mean median
one-stag chromogen note earli june releas fairli comprehens
includ assay valu minim confus remind fviii level
year year manag note slope declin steeper week
vs latter less dramat note similar earli peak eventu
settl seen program believ could side settl
management continu expect express stabil point hemophilia data other
durabl yr fviii vs potenti endoplasm reticulum er stress
note consciou phenomenon design vector purpos pair less
aggress promot higher dose vs stronger promot lower dose far compani
abl document er stress
acceler approv decis track though like wont see data real
time interim data acceler approv cohort mid year
complet enrol begin year support decis management underscor
commit announc decis necessarili provid data support
threshold success establish note criteria win
unequivoc establish fda agre bar though hasnt said
patient whether that mean median regardless confid compani abl
reach threshold base level observ mo
side readi go bioreactor suppli
patient dose per year cog usual rang scale
year remind compani use baculo system manufactur aav see
advantag feasibl scale titer among thing overal product process
take week final product frozen testing/analyt run
schedul develop individu valid test character product demonstr
compar batch
page analyst certif import disclosur
earlier stage pipelin pku ind track year could dmd next pku
gene therapi program enter clinic commerci materi benefit significantli
experi valrox beyond hasnt comment whether next ind gene
therapi small molecul someth els point toward data present day fa
also highlight on-going work aso significantli increas dystrophin express well
novel capsid uniqu muscl trophic
page analyst certif import disclosur
bold buy updat xlmtm regulatori path come
evp cfo dr john gray svp cso
takeaway upcom xlmtm data updat asgct may et includ
biopsi data higher dose cohort key data point help compani decid
dose move forward decis dose may readi meet given data
hot press management track final bla plan newli announc
program dmd bold note plan aggress develop far behind
may seem compani intern manufactur capabl continu see uniqu
valuabl asset key factor abil acceler develop bottom line continu like
bold share head near term asgct updat expect regulatori pipelin progress
asgct updat robust week biopsi cohort week biopsi
cohort bold process get asgct present togeth confirm
biopsi data readi meet remind cohort data alreadi near normal
protein express normal near normal histolog compani decid investig
higher dose given fda gener like see explor dose management reiter could
lead faster path approv faster bla review
focu next round fda discuss sampl size durat requir potenti
approv biopsi data hand dose decis expect addit
discuss fda help final regulatori path interact agenc alreadi help
determin endpoint interest announc earlier year bold note crux upcom
discuss sampl size compani continu pretti aggress view
given sever diseas unmet need power data compani note
patient enrol natur histori studi could facilit rapid enrol
bold manufactur also readi go compani current scale serum free
mammalian suspens process bold enter clinic xlmtm use process
uniqu gene therapi space initi patient often treat academ process yet
optim help simplifi regulatori side thing compar transit
issu also import strateg bold abil quickli get move dmd manufactur
side factor success get program given competit process
pomp make use new promot track follow setback
initi program compani chang promot ensur right level express right
place compani hasnt gotten specif competit reason continu believ
approach target muscl heart superior liver target approach
dmd compani continu believ abl move quickli superior approach
vs microdystrophin start academ product bold
transit platform time compani look similar endpoint program
addit could demonstr benefit full length dystrophin histolog current
exon skip approach gener prove concept variou efficaci profil also highlight
page analyst certif import disclosur
limit approach durabl durabl aav vector episom
vector rna set though patholog dmd vs xlmtm may increas import
earli treatment addit exon skip program collabor undisclos partner
could proceed even rapidli given synergi preclin manufactur program
page analyst certif import disclosur
derm buy qbrexza updat reassur lebri phase plan
track detail phase data eadv
compani particip tom wiggan ceo eugen bauer lui pena cdo aurora svp
medic affair lori lyons-william head commerci christoph griffith chief busi
takeaway focu meet next step lebri post phase result
recent revers qbrexza volum growth follow termin co-pay card believ
derm qbrexza commerci plan improv drug long-term commerci return post
transit remain particularli enthusiast lebri clinic profil atop dermat opportun
indic well potenti strateg valu lebri could offer larger biopharma
packag submiss almiral remain track management continu expect deliveri
lebrikizumab clinic packag almiral nc mid-year trigger clock
almiral opt-in licens lebri eu upon opt-in dermira receiv payment
addit upon initi global phase current reflect model management
highlight opportun monet lebrikizumab region outsid us eu includ
china japan epidemiolog data suggest rate ad popul similar
us recent epidemiolog work dr jonathan silverberg suggest overal rate global
atop dermat derm epidemiolog work done ahead phase result suggest
patient atop dermat us moder sever diseas compar
seen dermatologist like skew fact moder sever patient
like seek medic help condit
addit data like present eadv madrid spain octob accord
management management plan discuss data alreadi disclos well key secondari endpoint like sleep lost
time cours respons pruriti dermira done work show re-sensit
sensori neuron abat hit lebrikizumab de-sensit management also
confid regard safeti data lebri includ low rate conjunct low number
phase design derm focus set highest efficaci bar possibl capit
longer durat mainten option well excel safeti compani
focus optim efficaci also look way differenti includ onset action once-
monthli mainten dose safeti phase design wasnt disclos mgmt base case
assum larg ph patient random one dose induct phase two
dose mainten phase mg management target end phase meet mid-
year continu expect initi global phase studi back half
readout discuss fda includ number patient durat studi
view could opportun acceler program fda sign smaller number
patient shorter durat studi vs primari endpoint given overal safeti
databas lebrikizumab patient management believ program necessari
deliv highly-pow success phase program accord management core pivot program
cost broader program includ studi lebri topic
corticosteroid pediatr drug suppli work etc would
qbrexza declin follow termin co-pay expect rx impact transit
limit hurt brand long-term growth prospect derm
page analyst certif import disclosur
investor alarm last week decis termin qbrexza co-pay program
termin april result reduct week week volum management base decis
strong earli fundament qbrexza launch includ commerci live cover
month launch earlier management expect strong qbrexza adopt across
uniqu prescrib market expans overal month
ahead compani dtc campaign compar market management note flat
decad management note patient werent get access co-pay walk-away rate
pharmaci vs walk-away rate patient receiv co-pay card
derm note despit broad commerci insur coverag use co-pay card vastli
exceed expect use given substanti chang coverag begin decemb
management expect prescript disrupt short-liv limit first sever week
second quarter despit volum disrupt management expect q/q prescript volum increas
includ addit management expect gross net improv
result per script profit improv elimin co-pay
earli refil rate posit earli test baked-in assumpt qbrexza peak opportun
march overal prescript volum grew m/m refil grow vs new prescript rate
compani view posit sign patient accumul prescript
refil mgmt ground refil per year believ soon say whether
refil assumpt consist see real-world management believ back half
year could better posit revisit refil rate assumpt peak qbrexza sale
page analyst certif import disclosur
buy confid cabometyx sale growth life-cycle
compani particip michael morrissey presid ceo chri senner cfo andrew peter vice-president
strategi susan hubbard evp public affair ir
takeaway compani remain confid metyx growth within kidney
cancer rcc commerci liver cancer highli synergist rcc given
prescrib overlap market system therapi take time grow could
potenti lead cabo acceler approv differenti thyroid cancer dtc per convers
regul next wave pivot trial seek cabo label expans start later year
pancreat neuroendocrin tumor net carcinoid top mind bladder lung also
potenti indic interest busi develop perspect narrow focu
toward under-appreci distress asset later-clin stage develop mindset similar
valu investor
management remain confid cabo continu growth potenti rcc mrk
evalu pembrolizumab axitinib rais bar front-lin rcc compani maintain
view well posit growth rcc base exist labl treatment
choic follow progress io-bas line therapi still low market penetr line rcc
signific growth potenti on-going plan phase trial line rcc combin
either opdivo opdivo yervoy respect management note opdivo
leader within rcc compar favor inlyta keytruda individu
compon could potenti read well on-going trial management also
point year presenc brand awar rcc market could potenti
commerci tailwind succeed still compani emphas primari goal
ensur rcc patient receiv point sinc major patient cycl least
line therapi management note new clinic data present confirm io therapi
follow io therapi limit activ rcc cement cabo posit standard care
rcc follow progress io therapi
cabometyx commerci synergist rcc given prescrib overlap market
system therapi take time grow caution need re-build system therapi
market medic oncologist histor share patient hepatologist
intervent radiologist limit treatment choic bayri sorafenib regorafenib
compani believ cabo launch trajectori slower achiev
rcc compani remain confid shift patient toward medic oncolog given cabo overal
surviv benefit rel poor long-term outcom local therapi tace
maintain shift may requir time near-term management believ posit
readout opdivo would favor read-through provid nice set-up
evalu tecentriq vs nexavar bayri frontlin
potenti acceler approv cabo dtc phase per preliminari
convers regul dtc opportun high synergi potenti given exel current
infrastructur familiar medullari thyroid carcinoma mtc huge popul
compani think layer potenti dtc label onto exist commerci team without addit
effort expens revenu opportun perspect compani hasnt provid guidanc
point current mtc larger patient pool dtc rel mtc recal cosmic-
multicent random double-blind placebo-control phase pivot trial aim enrol
page analyst certif import disclosur
approxim patient approxim site global interim analysi base orr
plan conduct first patient enrol
wave pivot trial pursu cabo label expans start later year particular
interest pnet carcinoid tumor given encourag phase ii data bladder lung cancer
remain potenti choic well though management caveat bladder market flux emerg
antibody-drug conjug fgfr inhibitor may wait see landscap
evolv prior make signific invest diseas compani view lung cancer
settl point despit complex want jump decis without care
evalu potenti combin partner appropri patient segment
busi develop perspect narrow focu toward under-valued
distress asset valu investor mindset compani continu look everyth
emphas greater interest disfavor later-stag clinic asset compani point cabo
posit late near-miss surviv endpoint cabo competitor dismiss
commerci potenti type asset seek
page analyst certif import disclosur
jans-pet volkmer vice-president research earli develop
takeaway phase ii result non-hodgkin lymphoma nhl eha
icml could potenti valid phase signal ftsv plan random pivot trial
nhl base-cas assumpt pend plan fda-discuss vidaza
combin data aml/md could potenti valid preclin data indic potenti
synergi trial solid tumor indic track addit updat guid
phase ii result non-hodgkin lymphoma nhl eha icml could
potenti valid phase signal manag note updat trial result includ result
deriv new patient roughli split evenli among mg/kg maintain dose
cohort dose cohort contain roughli equal number relapsed/refractori diffus larg b-cell
lymphoma dlbcl follicular luymphoma fl patient recal phase portion trial
previous highlight result publish new england journal medicin
novemb phase data avail date retuximab-refractroy nhl patient dose across
dose-cohort combin rituximab result cr rate
overal cr rate r/rdlbcl patient orr cr fl
regard upcom mid-year updat ftsv updat durat respons previous
present patient cohort well initi safeti efficaci data phase ii portion studi
ftsv management emphas base prior fda recommend phase ii portion includ
difficult treat patient vs phase car-t therapi in-elig like result slightli lower
efficaci rate vs previous report figur term efficaci bar ftsv point
trial potenti benchmark late stage r/rdlbcl indic orr mo month
ftsv plan random pivot trial nhl base-cas assumpt ftsv plan meet
fda discuss potenti regulatori strategi combin
r/rdlbcl r/rfl dlbcl differ option exist exampl random phase trial vs r-ice
second line patient manag encourag morphosi pursuit single-arm approv
combin revlimid line r/rdlbcl management consid acceler
approv strategi potenti upsid scenario point within r/rfl management point copiktra
vstm fl potenti benchmark demonstr orr cr rate result
vidaza combin data aml/md may includ patient safeti lead-in
expans cohort patient per manag manag guid present
monotherapi data relapsed/refractori aml md patient small cohort similar
prior phase updat present eha demonstr stabl diseas includ
one persist almost one year prior diseas progress stop therapi second cohort
combin vidaza celg line aml patient inelig induct
chemotherapi well untreat md patient ipss intermedi high risk ask potenti
benchmark management point monotherapi vidaza achiev cr/cri rate elderli untreat
aml patient slow onset respons management highlight preclin data aml provid
foundat vidaza combin trial
trial solid tumor indic track addit updat guid phase
ib/ii trial combin cetuximab patient colorect cancer phase ib trial
page analyst certif import disclosur
